Titlebook: Cardio-Oncology; The Clinical Overlap Gretchen G. Kimmick,Daniel J. Lenihan,Dawn L. Hers Book 2017 Springer International Publishing Switze

DIGN

書目名稱Cardio-Oncology影響因子(影響力)




書目名稱Cardio-Oncology影響因子(影響力)學(xué)科排名




書目名稱Cardio-Oncology網(wǎng)絡(luò)公開度




書目名稱Cardio-Oncology網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Cardio-Oncology被引頻次




書目名稱Cardio-Oncology被引頻次學(xué)科排名




書目名稱Cardio-Oncology年度引用




書目名稱Cardio-Oncology年度引用學(xué)科排名




書目名稱Cardio-Oncology讀者反饋




書目名稱Cardio-Oncology讀者反饋學(xué)科排名

dowagers-hump

Blazon

Vascular Complications of Cancer and Cancer Therapy,n improving cancer patient survival exists. This chapter discusses risk of and indications for thromboprophylaxis for venous thromboembolism in cancer patients and explores the epidemiologic and mechanistic relationship between certain cancer therapies and risk of vascular complications including venous thromboembolism and arterial thrombosis.

共和國

Geriatric Cardio-oncology,y is recommended as a strategy to improve outcomes. Aggressive screening of risk factors, early detection of cardiovascular injury, and close collaboration between oncologists and cardiologists are critical for optimizing cardiovascular health and cancer outcomes in older patients.

相符

sclera

sclera

Outwit

https://doi.org/10.1007/b137669ention of major national and international cardiology and oncology associations to the field of cardio-oncology. This chapter discusses how the partnership of these two medical subspecialties in the future will improve outcomes for cancer patients.

COST

Management of Chemotherapy-Associated Cardiomyopathy,re many well-documented, long-term cardiovascular complications of chemotherapy including cardiomyopathy, myocardial infarction, and arrhythmia [2]. This chapter will focus on the management of cancer treatment-induced cardiomyopathy.

標(biāo)準(zhǔn)